MedPath

Sildenafil Citrate Before Surgery in Improving Kidney Function in Patients With Kidney Cancer

Phase 1
Completed
Conditions
Kidney Tumor
Interventions
Other: placebo
Drug: sildenafil citrate
Procedure: therapeutic conventional surgery
Registration Number
NCT01950923
Lead Sponsor
Wake Forest University Health Sciences
Brief Summary

This randomized pilot clinical trial studies sildenafil citrate before surgery in improving kidney function in patients with kidney cancer. Sildenafil citrate may help protect the kidney from the side effects of surgery and improve kidney function after surgery.

Detailed Description

PRIMARY OBJECTIVES:

I. To assess accrual, retention, and participation rates for patients receiving sildenafil (sildenafil citrate) compared to placebo in patients undergoing robotic partial nephrectomy (RPN) for a suspected renal malignancy.

SECONDARY OBJECTIVES:

I. To evaluate individual alterations in glomerular filtration rate (GFR) at 24 hours, 48 hours and one month following RPN and compare these to the placebo group.

II. To evaluate individual alterations in proteinuria at 24 hours, 48 hours, one month and three months following RPN and compare these to the placebo group.

III. To measure between-group differences in estimated blood loss and hemoglobin concentration at 24 hours following RPN.

IV. To describe individual changes in blood pressure measurements as noted in the preoperative holding area, throughout the procedure and in the post-anesthesia care unit.

V. To describe between-group variations in vasopressor support or intravenous fluid requirements during the operative procedure.

VI. To compare overall complication rates (within 90 days postoperatively) between groups.

VII. To obtain a preliminary effect size of sildenafil on change in GFR at three months following RPN.

OUTLINE: Patients are randomized to 1 of 2 treatment arms.

ARM I: Patients receive sildenafil citrate orally (PO) before the initiation of standard robotic partial nephrectomy.

ARM II: Patients receive placebo PO before the initiation of standard robotic partial nephrectomy.

After completion of study treatment, patients are followed up at 1 and 3 months.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
30
Inclusion Criteria
  • Patients who are scheduled to undergo robotic partial nephrectomy for suspected renal malignancy
  • Ability to understand and the willingness to sign a written informed consent document
Read More
Exclusion Criteria
  • Patients with a history of coronary artery disease (including history of myocardial infarction or cardiac stents) or a history of inducible ischemic changes on any prior cardiac stress testing
  • History of adverse reactions to any phosphodiesterase (PDE) inhibitor (PDE type 5 inhibitor [PDE5i])
  • Any patient currently taking a PDE5i will be asked to refrain from use for one week prior to their surgery; patients who have used a PDE5i within 72 hours of surgery will be excluded
  • Pregnant women are excluded from this study
  • Patients with only one kidney
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Arm II (placebo)placeboPatients receive placebo PO before the initiation of standard robotic partial nephrectomy.
Arm I (sildenafil citrate)sildenafil citratePatients receive sildenafil citrate PO before the initiation of standard robotic partial nephrectomy.
Arm I (sildenafil citrate)therapeutic conventional surgeryPatients receive sildenafil citrate PO before the initiation of standard robotic partial nephrectomy.
Arm II (placebo)therapeutic conventional surgeryPatients receive placebo PO before the initiation of standard robotic partial nephrectomy.
Primary Outcome Measures
NameTimeMethod
Participation rateUp to 6 months

Reasons for declining enrollment to the study will be documented on the Declined Participation Form at the time patients are presented with the study.

Accrual rateUp to 6 months

Reasons for declining enrollment to the study will be documented on the Declined Participation Form at the time patients are presented with the study.

Retention rateUp to 3 months

Retention will be assessed by whether or not the patient attends his or her 1 and 3 month postoperative visits.

Secondary Outcome Measures
NameTimeMethod
Overall complication ratesUp to 90 days after RPN

Compared between the two study groups.

Preliminary effect size of sildenafil citrate on change in GFRAt 3 months
Change in GFRBaseline to up to 1 month

Regression analysis will be used; the change will be modeled, with adjustment for baseline GFR, to assess difference in the two study groups.

Estimated blood lossAt 24 hours after RPN

Compared between the two study groups.

Hemoglobin concentrationAt 24 hours after RPN

Compared between the two study groups.

Changes in blood pressure measurementsBaseline to up to 2 days after RPN

Compared between the two study groups.

Change in proteinuriaBaseline to up to 3 months

Compared between the two study groups.

Vasopressor support requirements during the operative procedureDuring RPN

Compared between the two study groups.

Intravenous fluid requirements during the operative procedureDuring RPN

Compared between the two study groups.

Trial Locations

Locations (1)

Comprehensive Cancer Center of Wake Forest University

🇺🇸

Winston-Salem, North Carolina, United States

© Copyright 2025. All Rights Reserved by MedPath